These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-002102-30 OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY AND EFFICACY OF CC-5013 MONOTHERAPY FOR SUBJECTS WITH MULTIPLE MYELOMA A COMPANION STUDY FOR STUDIES THAL-MM-003, CC-5013-MM-009, AND CC-5013-MM-010 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000454-73 A multicenter, randomized, double-blind, placebo-controlled, 3-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects wit... 2014-06-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004937-16 Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma 2009-01-05 bad-data
Reported results 2006-000057-22 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Study of CC-10004 in Subjects with Moderate-to-severe Plaque-Type Psoriasis 2007-02-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-001865-41 A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Pre... 2016-04-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001956-11 Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC 2010-09-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002517-12 A multicenter, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory Multiple Myeloma. 2009-11-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-004469-32 A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA 2010-02-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-004500-40 A phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the safety and Efficacy of Single-Agent Lenalidomide Revlimid in Subjects with Relapsed or Refractory Aggressive Non-Hodgkin s Lympho... 2011-04-27 bad-data
Reported results 2006-004532-73 A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA 2010-03-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-004553-17 A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR I... 2013-09-24 bad-data
Reported results 2006-004619-23 A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis 2009-05-08 due-trials
Reported results 2006-004785-14 A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First-Line Platinum-based Chemoth... 2009-01-31 due-trials
Listed as ongoing, but also has a completion date 2007-001626-27 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONI... 2017-09-05 bad-data
Ongoing, reported early 2007-002171-13 A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY T-CELL NON-HODGKIN’S LYMPHOMA not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-003989-18 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ... 2011-05-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004097-32 An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma 2014-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004823-39 A Phase III, Randomized, Open-Label, 3-Arm Study To Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four... 2016-07-14 bad-data
Not reported 2007-005670-31 A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are re... 2008-09-17 due-trials
Listed as ongoing, but also has a completion date 2007-007756-34 A Phase 2, multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent lenalidomide (Revlimid ®) in patients with mantle cell NHL who have relapsed or progressed aft... 2018-01-08 bad-data
Listed as ongoing, but also has a completion date 2008-003079-32 A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) VERSUS CHLORAMBUCIL AS FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PA... 2018-09-05 bad-data
Listed as ongoing, but also has a completion date 2008-003389-25 A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA 2018-10-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-006177-32 A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID) IN PATIENTS WITH MANTLE-CELL LYMPHOMA 2011-03-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-007969-23 A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER 2016-11-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-009836-54 A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study Of The Safety And Efficacy Of Different Lenalidomide (Revlimid) Dose Regimens In Subjects With Relapsed Or Refractory B-Cell Chr... 2017-09-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011305-17 A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas 2013-04-01 bad-data
Listed as ongoing, but also has a completion date 2009-011513-24 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION-DE... 2018-05-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012346-23 A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, STUDY OF AZACITIDINE (VIDAZA) VERSUS CONVENTIONAL CARE REGIMENS FOR THE TREATMENT OF OLDER SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA 2016-07-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012665-61 A Phase 2, open-label study to assess the efficacy and safety of lenalidomide in combination with cetuximab in pretreated subjects with KRAS mutant metastatic colorectal cancer 2011-01-25 bad-data
Listed as ongoing, but also has a completion date 2009-013483-38 A Phase 2/3 Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator’s Choice in Patients with Relapsed or Refractory Diffuse Large B-... 2018-04-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018385-23 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis 2017-01-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018386-32 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis 2017-01-27 bad-data
Listed as ongoing, but also has a completion date 2010-018965-42 A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED MYEL... 2018-05-15 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-019820-30 A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Ref... 2017-08-29 bad-data
Reported results 2010-019926-15 A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO COMPARE THE EFFICACY AND SAFETY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE RHEUMATOID ... 2012-09-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019941-24 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and a ... 2017-02-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-019991-55 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis 2016-11-22 bad-data
Reported results 2010-019992-30 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis 2016-11-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-020324-22 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who h... 2017-08-16 bad-data
Ongoing, reported early 2010-023040-32 An Open-Label, Single-Arm Rollover Study for Subjects Who Participated in Other Romidepsin Protocols not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-023047-15 A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4... 2016-11-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023343-16 Open-label, multi-center, single-arm study for the safety and efficacy of pomalidomide (CC-4047) monotherapy for subjects with refractory or relapsed and refractory multiple myeloma: a companion stu... 2014-07-31 bad-data
Ongoing 2011-001555-37 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyliti... not-yet-due
Ongoing 2011-004558-24 A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINISTER... not-yet-due
Ongoing 2011-005659-15 A Phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)- thalassemia not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-000859-14 A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to Se... 2016-04-04 bad-data
Ongoing 2012-001888-78 A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA not-yet-due
Ongoing 2012-002471-34 A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Bl... not-yet-due
Completed, report not yet due 2012-002601-22 AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC 2018-04-30 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-002714-40 A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF... 2017-04-13 bad-data
Ongoing 2012-003123-38 A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO... not-yet-due
Ongoing 2012-003457-28 A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subject... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-003788-23 A Phase 2 Multicenter, Randomized, Open Label, Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Swi... 2016-08-23 bad-data
Completed, reported early 2012-005805-36 A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Mye... 2017-05-18 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000113-20 A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUBJEC... 2016-10-28 bad-data
Ongoing 2013-000144-26 A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid ... not-yet-due
Ongoing 2013-001245-14 A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lympho... not-yet-due
Reported results 2013-001590-25 A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATIC A... 2016-11-17 due-trials
Ongoing 2013-001729-26 Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma not-yet-due
Ongoing 2013-001903-36 A PHASE 2 MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELO... not-yet-due
Not reported 2013-002291-41 A Randomized, Open Label, Multi-Center Phase 2 Study of nab-Paclitaxel versus Epigenetic Modifying Therapy of CC-486 with nab-Paclitaxel in Subjects with Chemotherapy Naïve Metastatic Melanoma 2014-01-31 due-trials
Ongoing 2013-003398-91 A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-003866-15 MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046 2015-06-16 bad-data
Ongoing 2013-004054-21 Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemo... not-yet-due
Ongoing 2014-000268-17 A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS ... not-yet-due
Ongoing 2014-001105-41 A Phase 2, open-label, multicenter study to assess safety and efficacy of second/third-line treatment with nab-paclitaxel (ABI-007) in combination with epigenetic modifying therapy of CC-486, or immun... not-yet-due
Listed as ongoing, but also has a completion date 2014-001408-23 NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT) 2018-04-26 bad-data
Reported results 2014-001745-25 A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic N... 2017-04-20 due-trials
Ongoing 2014-002108-25 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TR... not-yet-due
Ongoing 2014-002172-92 A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and youn... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-002320-27 A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclero... 2016-12-22 bad-data
Ongoing 2014-002388-13 A Phase 2, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety and activity of azacitidine and to compare azacitidine to historical controls in pediatric subjects ... not-yet-due
Ongoing 2014-002675-29 A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination with Durvalumab (MEDI4736)... not-yet-due
Ongoing 2014-002981-64 A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS not-yet-due
Ongoing 2014-003056-31 Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphoc... not-yet-due
Completed, report not yet due 2014-003220-52 A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Wo... 2017-11-21 not-yet-due
Ongoing 2014-003804-66 A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB-PACLITAXEL (ABRAXANE®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB-PACLITAXEL PLUS CARBOPLATIN IN SUBJ... not-yet-due
Ongoing 2014-005614-29 A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizuma... not-yet-due
Ongoing 2015-000319-41 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis not-yet-due
Ongoing 2015-000344-42 A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia H... not-yet-due
Ongoing 2015-001600-64 A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis not-yet-due
Listed as ongoing, but also has a completion date 2015-001924-40 A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with active... 2017-10-19 bad-data
Listed as ongoing, but also has a completion date 2015-001925-18 A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease. 2018-01-05 bad-data
Listed as ongoing, but also has a completion date 2015-001963-37 A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn’s disease 2018-01-04 bad-data
Ongoing 2015-002025-19 A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active... not-yet-due
Ongoing 2015-002500-91 A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis not-yet-due
Ongoing 2015-003224-31 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Tr... not-yet-due
Ongoing 2015-003225-33 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) versus Placebo in Adults with Non Transfusion Dependent Beta (... not-yet-due
Other 2015-003314-24 A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis not-yet-due
Reported results 2015-003364-36 A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects with Active Ulcerative Colitis. 2017-08-08 due-trials
Ongoing 2015-003454-41 A Phase 3, Double-Blind, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Placebo For The Treatment Of Anemia Due To IPSS-R Very Low, Low, Or Intermediate Risk Myel... not-yet-due
Ongoing 2015-003516-21 A Phase 1/2, open label, multicenter study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic lymp... not-yet-due
Ongoing 2015-003596-30 A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Highe... not-yet-due
Ongoing 2015-003951-23 A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus... not-yet-due
Other 2015-004831-11 A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subject... not-yet-due
Ongoing 2015-005173-20 A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or wi... not-yet-due
Ongoing 2016-000069-22 A PHASE 2, OPEN-LABEL, SINGLE-ARM ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO PARTICIPATED IN OTHER CELGENE SPONSORED CC-486 (ORAL AZACITIDINE) not-yet-due
Ongoing 2016-000860-40 A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAP... not-yet-due
Other 2016-001209-17 A PHASE 2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE SAFETY AND EFFICACY FOR THE COMBINATION OF DURVALUMAB (DURVA) AND DARATUMUMAB (DARA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE M... not-yet-due
Not reported 2016-001706-42 A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia 2017-03-01 due-trials
Listed as ongoing, but also has a completion date 2016-002903-25 A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. 2017-05-04 bad-data
Ongoing, reported early 2016-003073-18 A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults not-yet-due
Ongoing 2016-003400-31 Long-Term Follow-up Protocol for Subjects Treated with JCAR015 not-yet-due
Ongoing 2016-003473-17 A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, Followed by a 28-Week Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathi... not-yet-due
Ongoing 2016-003778-42 A Phase 1/2 Open-label, Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor-Risk (IPI ≥ 3) Diffuse Large B-Cell Lymphoma not-yet-due
Completed, report not yet due 2016-003801-32 Multicenter, Single-arm, Phase 2 Study to Determine the Efficacy for the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)... 2017-12-04 not-yet-due
Ongoing 2016-004574-17 A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS not-yet-due
Ongoing 2017-000106-38 A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma not-yet-due
Ongoing 2017-001465-24 Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. not-yet-due
No trial status on register 2017-002146-72 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric Subjects from 1 to ≤ 18 Years of Age with Relapsed o... bad-data
Ongoing 2017-002245-29 A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma not-yet-due
Ongoing 2017-003190-34 A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk M... not-yet-due
Ongoing 2017-004292-31 Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease not-yet-due
Ongoing 2017-004293-33 Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease not-yet-due
Ongoing 2017-004294-14 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease not-yet-due
Ongoing 2017-004295-55 A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease not-yet-due
Ongoing 2018-000929-32 A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive ... not-yet-due
Other 2018-001246-34 A phase 1B/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL not-yet-due